1
|
Rimailho L, Faria C, Domagala M, Laurent C, Bezombes C, Poupot M. γδ T cells in immunotherapies for B-cell malignancies. Front Immunol 2023; 14:1200003. [PMID: 37426670 PMCID: PMC10325712 DOI: 10.3389/fimmu.2023.1200003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/11/2023] [Indexed: 07/11/2023] Open
Abstract
Despite the advancements in therapy for B cell malignancies and the increase in long-term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results. γδ T cells, with their potential of functional plasticity and their anti-tumoral properties, emerged as good candidates for cancer immunotherapies. The representation and the diversity of γδ T cells in tissues and in the blood, in physiological conditions or in B-cell malignancies such as B cell lymphoma, chronic lymphoblastic leukemia or multiple myeloma, provides the possibility to manipulate them with immunotherapeutic approaches for these patients. In this review, we summarized several strategies based on the activation and tumor-targeting of γδ T cells, optimization of expansion protocols, and development of gene-modified γδ T cells, using combinations of antibodies and therapeutic drugs and adoptive cell therapy with autologous or allogenic γδ T cells following potential genetic modifications.
Collapse
Affiliation(s)
- Léa Rimailho
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - Carla Faria
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - Marcin Domagala
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - Camille Laurent
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
- Department of Pathology, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| | - Christine Bezombes
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - Mary Poupot
- Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| |
Collapse
|
2
|
Verstraete N, Marku M, Domagala M, Arduin H, Bordenave J, Fournié JJ, Ysebaert L, Poupot M, Pancaldi V. An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia. iScience 2023; 26:106897. [PMID: 37332613 PMCID: PMC10275988 DOI: 10.1016/j.isci.2023.106897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 12/07/2022] [Accepted: 05/12/2023] [Indexed: 06/20/2023] Open
Abstract
Monocyte-derived macrophages help maintain tissue homeostasis and defend the organism against pathogens. In tumors, recent studies have uncovered complex macrophage populations, including tumor-associated macrophages, which support tumorigenesis through cancer hallmarks such as immunosuppression, angiogenesis, or matrix remodeling. In the case of chronic lymphocytic leukemia, these macrophages are known as nurse-like cells (NLCs) and they protect leukemic cells from spontaneous apoptosis, contributing to their chemoresistance. We propose an agent-based model of monocyte differentiation into NLCs upon contact with leukemic B cells in vitro. We performed patient-specific model optimization using cultures of peripheral blood mononuclear cells from patients. Using our model, we were able to reproduce the temporal survival dynamics of cancer cells in a patient-specific manner and to identify patient groups related to distinct macrophage phenotypes. Our results show a potentially important role of phagocytosis in the polarization process of NLCs and in promoting cancer cells' enhanced survival.
Collapse
Affiliation(s)
- Nina Verstraete
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Malvina Marku
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Marcin Domagala
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Hélène Arduin
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Julie Bordenave
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Jean-Jacques Fournié
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Loïc Ysebaert
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, 31330 Toulouse, France
| | - Mary Poupot
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Vera Pancaldi
- CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Barcelona Supercomputing Center, Carrer de Jordi Girona, 29, 31, 08034 Barcelona, Spain
| |
Collapse
|
3
|
Degboé Y, Poupot R, Poupot M. Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and Cancer. Int J Mol Sci 2022; 23:ijms23031496. [PMID: 35163420 PMCID: PMC8835955 DOI: 10.3390/ijms23031496] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 01/19/2022] [Accepted: 01/20/2022] [Indexed: 12/12/2022] Open
Abstract
Monocytes and their tissue counterpart macrophages (MP) constitute the front line of the immune system. Indeed, they are able to rapidly and efficiently detect both external and internal danger signals, thereby activating the immune system to eradicate the disturbing biological, chemical, or physical agents. They are also in charge of the control of the immune response and account for the repair of the damaged tissues, eventually restoring tissue homeostasis. The balance between these dual activities must be thoroughly controlled in space and time. Any sustained unbalanced response of MP leads to pathological disorders, such as chronic inflammation, or favors cancer development and progression. In this review, we take advantage of our expertise in chronic inflammation, especially in rheumatoid arthritis, and in cancer, to highlight the pivotal role of MP in the physiopathology of these disorders and to emphasize the repolarization of unbalanced MP as a promising therapeutic strategy to control these diseases.
Collapse
Affiliation(s)
- Yannick Degboé
- Infinity, Université Toulouse, CNRS, INSERM, UPS, 31024 Toulouse, France;
- Département de Rhumatologie, CHU Toulouse, 31029 Toulouse, France
| | - Rémy Poupot
- Infinity, Université Toulouse, CNRS, INSERM, UPS, 31024 Toulouse, France;
- Correspondence:
| | - Mary Poupot
- Centre de Recherche en Cancérologie de Toulouse, Université Toulouse, INSERM, UPS, 31037 Toulouse, France;
| |
Collapse
|
4
|
Domagala M, Ysebaert L, Ligat L, Lopez F, Fournié JJ, Laurent C, Poupot M. IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells. Cancers (Basel) 2021; 14:cancers14010016. [PMID: 35008174 PMCID: PMC8750769 DOI: 10.3390/cancers14010016] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 12/15/2021] [Accepted: 12/17/2021] [Indexed: 12/04/2022] Open
Abstract
Simple Summary In in vitro co-cultures of CLL cells and nurse-like cells (NLC), protection against apoptosis is only provided by M2-like NLC, and not M1-like NLC. In this study, we propose that fine-tuning of NLC polarization (and therefore survival of leukemic cells) is dictated by a balance between IL-10 and TNF. Abstract Tumor-associated macrophages (TAMs) in chronic lymphocytic leukemia (CLL) are also called nurse-like cells (NLC), and confer survival signals through the release of soluble factors and cellular contacts. While in most patient samples the presence of NLC in co-cultures guarantees high viability of leukemic cells in vitro, in some cases this protective effect is absent. These macrophages are characterized by an “M1-like phenotype”. We show here that their reprogramming towards an M2-like phenotype (tumor-supportive) with IL-10 leads to an increase in leukemic cell survival. Inflammatory cytokines, such as TNF, are also able to depolarize M2-type protective NLC (decreasing CLL cell viability), an effect which is countered by IL-10 or blocking antibodies. Interestingly, both IL-10 and TNF are implied in the pathophysiology of CLL and their elevated level is associated with bad prognosis. We propose that the molecular balance between these two cytokines in CLL niches plays an important role in the maintenance of the protective phenotype of NLCs, and therefore in the survival of CLL cells.
Collapse
Affiliation(s)
- Marcin Domagala
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
| | - Loïc Ysebaert
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
- IUCT-O, 31000 Toulouse, France
| | - Laetitia Ligat
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
| | - Frederic Lopez
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
- IUCT-O, 31000 Toulouse, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France; (M.D.); (L.Y.); (L.L.); (F.L.); (J.-J.F.); (C.L.)
- Université Toulouse III Paul-Sabatier, 31400 Toulouse, France
- ERL 5294 CNRS, 31037 Toulouse, France
- Correspondence: ; Tel.: +33-582741662
| |
Collapse
|
5
|
Marku M, Verstraete N, Raynal F, Madrid-Mencía M, Domagala M, Fournié JJ, Ysebaert L, Poupot M, Pancaldi V. Insights on TAM Formation from a Boolean Model of Macrophage Polarization Based on In Vitro Studies. Cancers (Basel) 2020; 12:cancers12123664. [PMID: 33297362 PMCID: PMC7762229 DOI: 10.3390/cancers12123664] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 11/26/2020] [Accepted: 11/30/2020] [Indexed: 12/24/2022] Open
Abstract
Simple Summary The recent success of immunotherapy treatments against cancer relies on helping our own body’s defenses in the fight against tumours, namely reinvigorating the cancer killing action of T cells. Unfortunately, in a large proportion of patients these therapies are ineffective, in part due to the presence of other immune cells, macrophages, which are mis-educated by the cancer cells into promoting tumour growth. Here we start from an existing model of macrophage polarization and extend it to the specific conditions encountered inside a tumour by adding signals, receptors, transcription factors and cytokines that are known to be the key components in establishing the cancer cell-macrophage interaction. Then we use a mathematical Boolean model applied to a gene regulatory network of this biological process to simulate its temporal behaviour and explore scenarios that have not been experimentally tested so far. Additionally, the KO and overexpression simulations successfully reproduce the known experimental results while predicting the potential role of regulators (such as STAT1 and EGF) in preventing the formation of pro-tumoural macrophages, which can be tested experimentally. Abstract The tumour microenvironment is the surrounding of a tumour, including blood vessels, fibroblasts, signaling molecules, the extracellular matrix and immune cells, especially neutrophils and monocyte-derived macrophages. In a tumour setting, macrophages encompass a spectrum between a tumour-suppressive (M1) or tumour-promoting (M2) state. The biology of macrophages found in tumours (Tumour Associated Macrophages) remains unclear, but understanding their impact on tumour progression is highly important. In this paper, we perform a comprehensive analysis of a macrophage polarization network, following two lines of enquiry: (i) we reconstruct the macrophage polarization network based on literature, extending it to include important stimuli in a tumour setting, and (ii) we build a dynamical model able to reproduce macrophage polarization in the presence of different stimuli, including the contact with cancer cells. Our simulations recapitulate the documented macrophage phenotypes and their dependencies on specific receptors and transcription factors, while also unravelling the formation of a special type of tumour associated macrophages in an in vitro model of chronic lymphocytic leukaemia. This model constitutes the first step towards elucidating the cross-talk between immune and cancer cells inside tumours, with the ultimate goal of identifying new therapeutic targets that could control the formation of tumour associated macrophages in patients.
Collapse
Affiliation(s)
- Malvina Marku
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
- Correspondence: (M.M.); (V.P.); Tel.: +33-5-82-74-17-74 (M.M.)
| | - Nina Verstraete
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Flavien Raynal
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Miguel Madrid-Mencía
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Marcin Domagala
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Jean-Jacques Fournié
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Loïc Ysebaert
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, 31330 Toulouse, France
| | - Mary Poupot
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
| | - Vera Pancaldi
- INSERM, Centre de Recherches en Cancérologie de Toulouse, 2 Avenue Hubert Curien, 31037 Toulouse, France; (N.V.); (F.R.); (M.M.-M.); (M.D.); (J.-J.F.); (L.Y.); (M.P.)
- Université III Toulouse Paul Sabatier, Route de Narbonne, 31330 Toulouse, France
- Barcelona Supercomputing Center, Carrer de Jordi Girona, 29, 31, 08034 Barcelona, Spain
- Correspondence: (M.M.); (V.P.); Tel.: +33-5-82-74-17-74 (M.M.)
| |
Collapse
|
6
|
Laplagne C, Meddour S, Figarol S, Michelas M, Calvayrac O, Favre G, Laurent C, Fournié JJ, Cabantous S, Poupot M. Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer. Front Immunol 2020; 11:1396. [PMID: 32733462 PMCID: PMC7358576 DOI: 10.3389/fimmu.2020.01396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 06/01/2020] [Indexed: 11/25/2022] Open
Abstract
Vγ9Vδ2 T cells are known to be efficient anti-tumor effectors activated through phosphoantigens (PAg) that are naturally expressed by tumor cells or induced by amino bisphosphonates treatment. This PAg-activation which is TCR and butyrophilin BTN3A dependent can be modulated by NKG2D ligands, immune checkpoint ligands, adhesion molecules, and costimulatory molecules. This could explain the immune-resistance observed in certain clinical trials based on Vγ9Vδ2 T cells therapies. In NSCLC, encouraging responses were obtained with zoledronate administrations for 50% of patients. According to the in vivo results, we showed that the in vitro Vγ9Vδ2 T cell reactivity depends on the NSCLC cell line considered. If the PAg-pretreated KRAS mutated A549 is highly recognized and killed by Vγ9Vδ2 T cells, the EGFR mutated PC9 remains resistant to these killers despite a pre-treatment either with zoledronate or with exogenous BrHPP. The immune resistance of PC9 was shown not to be due to immune checkpoint ligands able to counterbalance NKG2D ligands or adhesion molecules such as ICAM-1 highly expressed by PC9. RHOB has been shown to be involved in the Vγ9Vδ2 TCR signaling against these NSCLC cell lines, in this study we therefore focused on its intracellular behavior. In comparison to a uniform distribution of RHOB in endosomes and at the plasma membrane in A549, the presence of large endosomal clusters of RHOB was visualized by a split-GFP system, suggesting that RHOB rerouting in the PC9 tumor cell could impair the reactivity of the immune response.
Collapse
Affiliation(s)
- Chloé Laplagne
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Sarah Meddour
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Sarah Figarol
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Marie Michelas
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Olivier Calvayrac
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Gilles Favre
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,IUCT-O, Toulouse, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,IUCT-O, Toulouse, France
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Stéphanie Cabantous
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| |
Collapse
|
7
|
Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Front Immunol 2019; 10:1943. [PMID: 31475004 PMCID: PMC6702952 DOI: 10.3389/fimmu.2019.01943] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 08/01/2019] [Indexed: 12/22/2022] Open
Abstract
Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (ADCC) in the peripheral blood of FL patients predict the outcome. However, their presence in FL biopsies, their activation and their role have been poorly investigated. Moreover, in vitro studies have not deciphered the exact signaling cascades triggered by NK cells in presence of anti-CD20 mAbs on both effector and target cells in a relevant FL model. We performed in silico analyses and ex vivo functional assays to determine the presence and the activation status of NK cells in FL biopsies. We modelized ADCC phenomenon by developing a co-culture model composed by 3D-cultured FL cells and NK cells. Thus, we investigated the biological effect of anti-CD20 mAbs by fluorescent microscopy and the phosphorylation status of survival pathways by cell bar coding phosphoflow in target cells. In parallel, we measured the status of activation of downstream FcγRIIIa signaling pathways in effector cells and their activation (CD69, perforin, granzyme B, IFNγ) by flow cytometry. We determined by in vivo experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice. Here, we show that functional NK cells infiltrate FL biopsies, and that their presence tends to correlate with the survival of FL patients. Using our 3D co-culture model, we show that rituximab and GA101 are able to promote degranulation, CD69 expression, IFNγ production and activate FcγRIIIa signaling cascade in NK cells, and inhibit survival pathways and induce apoptosis in FL cells. The effect of GA101 seems to be more pronounced as observed in vivo in a xenograft FL model. This study strongly supports the role of NK cells in FL and highlights the application of the 3D co-culture model for in vitro validation.
Collapse
Affiliation(s)
- Emilie Decaup
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - Cédric Rossi
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CHU Dijon, Hématologie Clinique, Hôpital François Mitterand, Dijon, France
| | - Pauline Gravelle
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Julie Bordenave
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - Marie Tosolini
- Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Anne Tourette
- INSERM1052/CNRS5286/Université Claude Bernard, Lyon, France
| | | | | | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - Christian Klein
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
| | | | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - Christine Bezombes
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| |
Collapse
|
8
|
Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, Valle C, Labourdette D, Cadot S, Quillet-Mary A, Poupot M, Laurent C, Ysebaert L, Meraviglia S, Dieli F, Merville P, Milpied P, Déchanet-Merville J, Fournié JJ. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci U S A 2019; 116:11906-11915. [PMID: 31118283 PMCID: PMC6576116 DOI: 10.1073/pnas.1818488116] [Citation(s) in RCA: 102] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
γδ T lymphocytes represent ∼1% of human peripheral blood mononuclear cells and even more cells in most tissues of vertebrates. Although they have important anticancer functions, most current single-cell RNA sequencing (scRNA-seq) studies do not identify γδ T lymphocytes because their transcriptomes at the single-cell level are unknown. Here we show that high-resolution clustering of large scRNA-seq datasets and a combination of gene signatures allow the specific detection of human γδ T lymphocytes and identification of their T cell receptor (TCR)Vδ1 and TCRVδ2 subsets in large datasets from complex cell mixtures. In t-distributed stochastic neighbor embedding plots from blood and tumor samples, the few γδ T lymphocytes appear collectively embedded between cytotoxic CD8 T and NK cells. Their TCRVδ1 and TCRVδ2 subsets form close yet distinct subclusters, respectively neighboring NK and CD8 T cells because of expression of shared and distinct cytotoxic maturation genes. Similar pseudotime maturation trajectories of TCRVδ1 and TCRVδ2 γδ T lymphocytes were discovered, unveiling in both subsets an unattended pool of terminally differentiated effector memory cells with preserved proliferative capacity, a finding confirmed by in vitro proliferation assays. Overall, the single-cell transcriptomes of thousands of individual γδ T lymphocytes from different CMV+ and CMV- donors reflect cytotoxic maturation stages driven by the immunological history of donors. This landmark study establishes the rationale for identification, subtyping, and deep characterization of human γδ T lymphocytes in further scRNA-seq studies of complex tissues in physiological and disease conditions.
Collapse
Affiliation(s)
- Gabriele Pizzolato
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
- Humanitas University, 20089 Rozzano (MI), Italy
- Department of Biopathology and Medical Biotechnologies, University of Palermo, 90133 Palermo, Italy
- Central Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, 90133 Palermo, Italy
| | - Hannah Kaminski
- University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, F-33076 Bordeaux, France
- Service de Néphrologie et Transplantation Rénale, Centre Hospitalo-Universitaire de Bordeaux, 33000 Bordeaux, France
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Don-Marc Franchini
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Fréderic Pont
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Fréderic Martins
- Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR1048, 31432 Toulouse, France
- Plateforme GeT, Genotoul, 31100 Toulouse, France
| | - Carine Valle
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Delphine Labourdette
- Plateforme GeT, Genotoul, 31100 Toulouse, France
- Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés, Université de Toulouse, CNRS, INRA, INSA, 31077 Toulouse, France
| | - Sarah Cadot
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Anne Quillet-Mary
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Loic Ysebaert
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| | - Serena Meraviglia
- Department of Biopathology and Medical Biotechnologies, University of Palermo, 90133 Palermo, Italy
- Central Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, 90133 Palermo, Italy
| | - Francesco Dieli
- Department of Biopathology and Medical Biotechnologies, University of Palermo, 90133 Palermo, Italy
- Central Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, 90133 Palermo, Italy
| | - Pierre Merville
- University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, F-33076 Bordeaux, France
- Service de Néphrologie et Transplantation Rénale, Centre Hospitalo-Universitaire de Bordeaux, 33000 Bordeaux, France
| | - Pierre Milpied
- Aix Marseille University, CNRS, INSERM, Centre d' Immunologie de Marseille-Luminy, 13007 Marseille, France
| | | | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France;
- Toulouse University, 31000 Toulouse, France
- ERL 5294 CNRS, 31024 Toulouse, France
- Institut Universitaire du Cancer-Oncopole de Toulouse, 31100 Toulouse, France
- Laboratoire d'Excellence 'TOUCAN', Toulouse, France
- Programme Hospitalo, Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France
- Institut Carnot Lymphome CALYM, 69495 Lyon-Pierre Bénite, France
| |
Collapse
|
9
|
Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini DM, Laurent C, Morin R, Lagarde JM, Ysebaert L, Ligat L, Jean C, Savina A, Klein C, Céspedes AM, Perez-Galan P, Fournié JJ, Bezombes C. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology 2018; 8:1554175. [PMID: 30723586 DOI: 10.1080/2162402x.2018.1554175] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 11/21/2018] [Accepted: 11/22/2018] [Indexed: 12/20/2022] Open
Abstract
Follicular lymphoma (FL) is a common non Hodgkin's lymphoma subtype in which immune escape mechanisms are implicated in resistance to chemo-immunotherapy. Although molecular studies point to qualitative and quantitative deregulation of immune checkpoints, in depth cellular analysis of FL immune escape is lacking. Here, by functional assays and in silico analyses we show that a subset of FL patients displays a 'high' immune escape phenotype. These FL cases are characterized by abundant infiltration of PD1+ CD16+ TCRVγ9Vδ2 γδ T lymphocytes. In a 3D co-culture assay (MALC), γδ T cells mediate both direct and indirect (ADCC in the presence of anti-CD20 mAbs) cytolytic activity against FL cell aggregates. Importantly, PD-1, which is expressed by most FL-infiltrating γδ T lymphocytes with ADCC capacity, impairs these functions. In conclusion, we identify a PD1-regulated γδ T cell cytolytic immune component in FL. Our data provide a treatment rational by PD-1 blockade aimed at boosting γδ T cell anti-tumor functions in FL.
Collapse
Affiliation(s)
- Cédric Rossi
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France.,CHU Dijon, Hématologie clinique, Hôpital François Mitterand, Dijon, France
| | - Pauline Gravelle
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France.,Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Emilie Decaup
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France
| | - Julie Bordenave
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Don-Marc Franchini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France.,Department of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | | | - Loïc Ysebaert
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France.,Department of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Laetitia Ligat
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Christine Jean
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France
| | | | - Christian Klein
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
| | - Alba Matas Céspedes
- Hematology-Oncology department, IDIBAPS, Center Esther Koplowitz, Barcelona, Spain
| | - Patricia Perez-Galan
- Hematology-Oncology department, IDIBAPS, Center Esther Koplowitz, Barcelona, Spain
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France
| | - Christine Bezombes
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, France.,Laboratoire d'Excellence TOUCAN, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France.,CALYM Carnot Institute, Pierre-Bénite, France
| |
Collapse
|
10
|
Abstract
Interleukin-33 (IL-33), considered as an alarmin released upon tissue stress or damage, is a member of the IL-1 family and binds the ST2 receptor. First described as a potent initiator of type 2 immune responses through the activation of T helper 2 (TH2) cells and mast cells, IL-33 is now also known as an effective stimulator of TH1 immune cells, natural killer (NK) cells, iNKT cells, and CD8 T lymphocytes. Moreover, IL-33 was shown to play an important role in several cancers due to its pro and anti-tumorigenic functions. Currently, IL-33 is a possible inducer and prognostic marker of cancer development with a direct effect on tumor cells promoting tumorigenesis, proliferation, survival, and metastasis. IL-33 also promotes tumor growth and metastasis by remodeling the tumor microenvironment (TME) and inducing angiogenesis. IL-33 favors tumor progression through the immune system by inducing M2 macrophage polarization and tumor infiltration, and upon activation of immunosuppressive cells such as myeloid-derived suppressor cells (MDSC) or regulatory T cells. The anti-tumor functions of IL-33 also depend on infiltrated immune cells displaying TH1 responses. This review therefore summarizes the dual role of this cytokine in cancer and suggests that new proposals for IL-33-based cancer immunotherapies should be considered with caution.
Collapse
Affiliation(s)
- Jean-Jacques Fournié
- INSERM UMR 1037 Centre de Recherche en Cancérologie de Toulouse (CRCT), ERL 5294 CNRS, Université Toulouse III Paul Sabatier, Laboratoire d'excellence Toucan, Toulouse, France
| | - Mary Poupot
- INSERM UMR 1037 Centre de Recherche en Cancérologie de Toulouse (CRCT), ERL 5294 CNRS, Université Toulouse III Paul Sabatier, Laboratoire d'excellence Toucan, Toulouse, France
| |
Collapse
|
11
|
Franchini DM, Michelas M, Lanvin O, Poupot M, Fournié JJ. BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference. Eur J Immunol 2017; 47:954-957. [PMID: 28597565 DOI: 10.1002/eji.201747058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 04/21/2017] [Accepted: 04/26/2017] [Indexed: 11/11/2022]
Abstract
Human blood γδ T lymphocytes express TCRVγ9Vδ2 and respond to nonpeptide phosphoantigens (PAgs) by a mysterious mechanism involving the BTN3A1 (CD277) molecule . BTN3A1 is a butyrophilin-like protein related to CD80, PD-L1, and MHC, and is either a presenting or a co-stimulatory molecule for PAgs. Although the precise roles and molecular interactions with the TCRVγ9Vδ2 are currently not determined, it is commonly thought that all TCRVγ9Vδ2 lymphocytes 'see' PAg and BTN3A1 together, presumably in a single molecular recognition event. But whether this recognition event could be reproduced in a simplified model was not addressed in previous studies. In this issue, Starick et al. (Eur. J. Immunol. 2017. 47: 982-992) compared the response of three TCRVγ9Vδ2 pairs of murine and human cell transfectants to PAg and anti-BTN3A1 antibodies using IL-2 release as a readout. The authors found that although the two murine transfectants responded similarly to either stimuli, one murine TCRVγ9Vδ2 transfectant reacted to PAgs but not to anti-BTN3A1 (mAb 20.1). Human transductants behave in a similar fashion, demonstrating that TCRVγ9Vδ2 lymphocytes differentiate PAg and BTN3A1 signals, while species of the transductants unmask this differential sensitivity. Indeed, understanding the puzzling mode of antigen recognition by γδ T lymphocytes will be essential for developing γδ T-cell-based immunotherapies, and the authors of this study now demonstrate that TCRVγ9Vδ2 lymphocytes are able to differentiate the PAg and BTN3A1 stimuli.
Collapse
Affiliation(s)
- Don-Marc Franchini
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Marie Michelas
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Olivia Lanvin
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Jean Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| |
Collapse
|
12
|
Duault C, Betous D, Bezombes C, Roga S, Cayrol C, Girard JP, Fournié JJ, Poupot M. IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model. Eur J Immunol 2017; 47:2137-2141. [PMID: 28741710 DOI: 10.1002/eji.201747093] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 06/13/2017] [Accepted: 07/21/2017] [Indexed: 01/22/2023]
Abstract
From several years, the anticancer effects of Vγ9 T lymphocytes make these cells good candidates for cancer immunotherapies. However, the proved efficacy of γδ Τ cell-based cancer immunotherapies in some clinical trials was minimized due to the inherent toxicity of IL-2, which is essential for the combination therapy with Phosphoantigen (PAg). Recently, we showed that IL-33, a γ chain receptor-independent cytokine, was able to induce the in vitro proliferation of PAg-activated Vγ9 T cells, which were fully functional expressing IFN-γ and TNF-α and showing in vitro anti-tumor cytotoxicity. We proposed IL-33 as an alternative to IL-2 for Vγ9 T cell-based cancer immunotherapies, and have therefore evaluated the efficacy of this cytokine in preclinical investigations. This study shows that human Vγ9 T cells are able to proliferate in a mouse model with the combination of PAg and rhIL-33, and that IL-33-expanded Vγ9 T cells can prevent tumor growth in a mouse lymphoma model.
Collapse
Affiliation(s)
- Caroline Duault
- INSERM UMR1037-Cancer Research Center of Toulouse, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Laboratoire d'excellence Toucan.,Stanford University School of Medicine, Stanford, CA, USA
| | - Delphine Betous
- INSERM UMR1037-Cancer Research Center of Toulouse, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Laboratoire d'excellence Toucan
| | - Christine Bezombes
- INSERM UMR1037-Cancer Research Center of Toulouse, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Laboratoire d'excellence Toucan
| | - Stéphane Roga
- Laboratoire d'excellence Toucan.,CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
| | - Corinne Cayrol
- Laboratoire d'excellence Toucan.,CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
| | - Jean-Philippe Girard
- Laboratoire d'excellence Toucan.,CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
| | - Jean-Jacques Fournié
- INSERM UMR1037-Cancer Research Center of Toulouse, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Laboratoire d'excellence Toucan
| | - Mary Poupot
- INSERM UMR1037-Cancer Research Center of Toulouse, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Laboratoire d'excellence Toucan
| |
Collapse
|
13
|
Rossi C, Decaup E, Gravelle P, Tosolini M, Franchini D, Laurent C, Bordenave J, Ligat L, Jean C, Pont F, Savina A, Klein C, Perez-Galan P, Poupot M, Fournié J, Bezombes C. PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Rossi
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - E. Decaup
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | | | - M. Tosolini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - D. Franchini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - C. Laurent
- Pathology Department, IUCT; Toulouse France
| | - J. Bordenave
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - L. Ligat
- Pôle Technologique, CRCT; Toulouse France
| | - C. Jean
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - F. Pont
- Pôle Technologique, CRCT; Toulouse France
| | - A. Savina
- SAS, Roche, Boulogne Billancourt; France
| | - C. Klein
- Glycart, Roche-Glycart; Basel Switzerland
| | - P. Perez-Galan
- Center Esther Koplowitz Hematology-Oncology Department, IDIBAPS; Barcelona Spain
| | - M. Poupot
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - J. Fournié
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| | - C. Bezombes
- Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM; Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Centre de Recherches en Cancérologie de Toulouse (CRCT); Toulouse France
| |
Collapse
|
14
|
Tosolini M, Pont F, Poupot M, Vergez F, Nicolau-Travers ML, Vermijlen D, Sarry JE, Dieli F, Fournié JJ. Assessment of tumor-infiltrating TCRV γ9V δ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 2017; 6:e1284723. [PMID: 28405516 DOI: 10.1080/2162402x.2017.1284723] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 01/12/2017] [Accepted: 01/13/2017] [Indexed: 10/20/2022] Open
Abstract
Most human blood γδ cells are cytolytic TCRVγ9Vδ2+ lymphocytes with antitumor activity. They are currently investigated in several clinical trials of cancer immunotherapy but so far, their tumor infiltration has not been systematically explored across human cancers. Novel algorithms allowing the deconvolution of bulk tumor transcriptomes to find the relative proportions of infiltrating leucocytes, such as CIBERSORT, should be appropriate for this aim but in practice they fail to accurately recognize γδ T lymphocytes. Here, by implementing machine learning from microarray data, we first improved the computational identification of blood-derived TCRVγ9Vδ2+ γδ lymphocytes and then applied this strategy to assess their abundance as tumor infiltrating lymphocytes (γδ TIL) in ∼10,000 cancer biopsies from 50 types of hematological and solid malignancies. We observed considerable inter-individual variation of TCRVγ9Vδ2+γδ TIL abundance both within each type and across the spectrum of cancers tested. We report their prominence in B cell-acute lymphoblastic leukemia (B-ALL), acute promyelocytic leukemia (M3-AML) and chronic myeloid leukemia (CML) as well as in inflammatory breast, prostate, esophagus, pancreas and lung carcinoma. Across all cancers, the abundance of αβ TILs and TCRVγ9Vδ2+ γδ TILs did not correlate. αβ TIL abundance paralleled the mutational load of tumors and positively correlated with inflammation, infiltration of monocytes, macrophages and dendritic cells (DC), antigen processing and presentation, and cytolytic activity, in line with an association with a favorable outcome. In contrast, the abundance of TCRVγ9Vδ2+ γδ TILs did not correlate with these hallmarks and was variably associated with outcome, suggesting that distinct contexts underlie TCRVγ9Vδ2+ γδ TIL and αβ TIL mobilizations in cancer.
Collapse
Affiliation(s)
- Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France; Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; Institut Universitaire du Cancer de Toulouse (IUCT), Toulouse, France
| | - Frédéric Pont
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - François Vergez
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Institut Universitaire du Cancer de Toulouse (IUCT), Toulouse, France
| | | | - David Vermijlen
- Central Laboratory for Advanced Diagnostics and Biomedical Research (CLADIBIOR), University of Palermo , Palermo, Italy
| | - Jean-Emmanuel Sarry
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| | - Francesco Dieli
- Department of Biopharmacy - Institute for Medical Immunology (IMI), Université Libre de Bruxelles , Bruxelles, Belgium
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France; INSERM U1037-Université Paul Sabatier-CNRS ERL5294, Université de Toulouse, Toulouse, France; Laboratoire d'Excellence TOUCAN, Toulouse, France; Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, France
| |
Collapse
|
15
|
Boissard F, Tosolini M, Ligat L, Quillet-Mary A, Lopez F, Fournié JJ, Ysebaert L, Poupot M. Nurse-like cells promote CLL survival through LFA-3/CD2 interactions. Oncotarget 2016; 8:52225-52236. [PMID: 28881725 PMCID: PMC5581024 DOI: 10.18632/oncotarget.13660] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 11/18/2016] [Indexed: 11/30/2022] Open
Abstract
In the tumoral micro-environment (TME) of chronic lymphocytic leukemia (CLL), nurse-like cells (NLC) are tumor-associated macrophages which play a critical role in the survival and chemoresistance of tumoral cells. This pro-survival activity is known to involve soluble factors, but few data are available on the relative role of cells cross-talk. Here, we used a transcriptome-based approach to systematically investigate the expression of various receptor/ligand pairs at the surface of NLC/CLL cells. Their relative contribution to CLL survival was assessed both by fluorescent microscopy to identify cellular interactions and by the use of functional tests to measure the impact of uncoupling these pairs with blocking monoclonal antibodies. We found for the first time that lymphocyte function-associated antigen 3 (LFA-3), expressed in CLL at significantly higher levels than in healthy donor B-cells, and CD2 expressed on NLC, were both key for the specific pro-survival signals delivered by NLC. Moreover, we found that NLC/CLL interactions induced the shedding of soluble LFA-3. Importantly, in an exploratory cohort of 60 CLL patients receiving frontline immunochemotherapy, increased levels of soluble LFA-3 were found to correlate with shorter overall survival. Altogether, these data suggest that LFA-3/CD2 interactions promote the survival of CLL cells in the tumor microenvironment.
Collapse
Affiliation(s)
- Frédéric Boissard
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France
| | - Marie Tosolini
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France
| | - Laetitia Ligat
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France.,Pole Technologique CRCT, Plateau Imagerie, Toulouse, France
| | - Anne Quillet-Mary
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France
| | - Frederic Lopez
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France.,Pole Technologique CRCT, Plateau Imagerie, Toulouse, France
| | - Jean-Jacques Fournié
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France
| | - Loic Ysebaert
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France.,IUCT-Oncopole, Toulouse, France
| | - Mary Poupot
- CRCT UMR1037 INSERM-ERL 5294 CNRS-Université Toulouse III Paul Sabatier, Toulouse, France
| |
Collapse
|
16
|
Poupot M, Turrin CO, Caminade AM, Fournié JJ, Attal M, Poupot R, Fruchon S. Poly(phosphorhydrazone) dendrimers: yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma. Nanomedicine 2016; 12:2321-2330. [PMID: 27498187 DOI: 10.1016/j.nano.2016.07.009] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Revised: 05/04/2016] [Accepted: 07/18/2016] [Indexed: 12/28/2022]
Abstract
Human natural killer (NK) cells play a key role in anti-cancer and anti-viral immunity, but their selective amplification in vitro is extremely tedious to achieve and remains one of the most challenging problems to solve for efficient NK cell-based immuno-therapeutic treatments against malignant diseases. Here we report that, when added to ex vivo culture of peripheral blood mononuclear cells from healthy volunteers or from cancer patients with multiple myeloma, poly (phosphorhydrazone) dendrimers capped with amino-bis(methylene phosphonate) end groups enable the efficient proliferation of NK cells with anti-cancer cytotoxicity in vivo. We also show that the amplification of the NK population relies on the preliminary activation of monocytes in the framework of a multistep cross-talk between monocytes and NK cells before the proliferation thereof. Thus poly(phosphorhydrazone) dendrimers represent a novel class of extremely promising drugs to develop NK-cell based anti-cancer therapies.
Collapse
Affiliation(s)
- Mary Poupot
- Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, CNRS, INSERM, UPS, France
| | | | | | - Jean-Jacques Fournié
- Centre de Recherche en Cancérologie de Toulouse, Université de Toulouse, CNRS, INSERM, UPS, France
| | - Michel Attal
- Institut Universitaire du Cancer de Toulouse-Oncopôle, Université de Toulouse, CNRS, INSERM, UPS, France
| | - Rémy Poupot
- Centre de Physiopathologie de Toulouse-Purpan, Université de Toulouse, CNRS, INSERM, UPS, France
| | - Séverine Fruchon
- Centre de Physiopathologie de Toulouse-Purpan, Université de Toulouse, CNRS, INSERM, UPS, France.
| |
Collapse
|
17
|
Boissard F, Laurent C, Ramsay AG, Quillet-Mary A, Fournié JJ, Poupot M, Ysebaert L. Nurse-like cells impact on disease progression in chronic lymphocytic leukemia. Blood Cancer J 2016; 6:e381. [PMID: 26771807 PMCID: PMC4742625 DOI: 10.1038/bcj.2015.108] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- F Boissard
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - C Laurent
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.,Department of Haematology, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| | - A G Ramsay
- Department of Haemato-Oncology, Division of Cancer Studies, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Quillet-Mary
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - J-J Fournié
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - M Poupot
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France
| | - L Ysebaert
- CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.,Department of Haematology, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| |
Collapse
|
18
|
Duault C, Franchini DM, Familliades J, Cayrol C, Roga S, Girard JP, Fournié JJ, Poupot M. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism. J Immunol 2015; 196:493-502. [PMID: 26608919 DOI: 10.4049/jimmunol.1500260] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 10/15/2015] [Indexed: 01/05/2023]
Abstract
The availability of specific stimuli to induce the anticancer cytotoxicity of human TCRVγ9-expressing T lymphocytes has allowed the development of γδ T cell-based cancer immunotherapies. However, the stringent dependence of such strategies on the inherently toxic IL-2 has raised safety concerns for patients, justifying a search for alternative methods for inducing γδ T cell stimulation. IL-33 is a γ-chain receptor-independent cytokine of the IL-1 superfamily that is expressed by endothelial cells from a tumor microenvironment and can sustain Th1 and Th2 immune responses. Therefore, we investigated its ability to support the stimulation of human TCRVγ9(+) γδ T cells. In this study, we report that IL-33 efficiently sustained the in vitro activation of Vγ9 T lymphocytes by synthetic phosphoantigens, zoledronate, and a BTN3A1 Ab in the absence of an exogenous supply of IL-2. IL-33 was as potent as IL-2 in allowing the proliferative amplification of Vγ9 T cells isolated from PBMC following activation by the synthetic phosphoantigen bromohydrin pyrophosphate. IL-33 also induced an identical maturation into TNF-α- and IFN-γ-producing Th1 effector memory cells, and IL-33-stimulated cells showed an equivalent cytotoxicity for various tumor cells in vitro. Finally, we found that the bioactivity of IL-33 on the Vγ9 T cell was indirectly mediated through contact with CD4 T cells and IL-2 production by CD4 T cells and Vγ9 T cells themselves. These data posit IL-33 as an alternative to IL-2 for Vγ9 T cell-based cancer immunotherapies.
Collapse
Affiliation(s)
- Caroline Duault
- INSERM UMR 1037, Centre de Recherches en Cancérologie de Toulouse, 31037 Toulouse, France; Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; CNRS ERL 5294, 31024 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and
| | - Don Marc Franchini
- INSERM UMR 1037, Centre de Recherches en Cancérologie de Toulouse, 31037 Toulouse, France; Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; CNRS ERL 5294, 31024 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and
| | - Julien Familliades
- INSERM UMR 1037, Centre de Recherches en Cancérologie de Toulouse, 31037 Toulouse, France; Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; CNRS ERL 5294, 31024 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and
| | - Corinne Cayrol
- Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France
| | - Stéphane Roga
- Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France
| | - Jean-Philippe Girard
- Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and CNRS UMR 5089, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France
| | - Jean-Jacques Fournié
- INSERM UMR 1037, Centre de Recherches en Cancérologie de Toulouse, 31037 Toulouse, France; Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; CNRS ERL 5294, 31024 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and
| | - Mary Poupot
- INSERM UMR 1037, Centre de Recherches en Cancérologie de Toulouse, 31037 Toulouse, France; Université Toulouse III - Paul Sabatier, 31062 Toulouse, France; CNRS ERL 5294, 31024 Toulouse, France; TOUCAN Laboratoire d'Excellence Toulouse Cancer, 31024 Toulouse, France; and
| |
Collapse
|
19
|
Boissard F, Fournié JJ, Quillet-Mary A, Ysebaert L, Poupot M. Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients. Blood Cancer J 2015; 5:e355. [PMID: 26430726 PMCID: PMC4635187 DOI: 10.1038/bcj.2015.74] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- F Boissard
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.,Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France
| | - J-J Fournié
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.,Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France
| | - A Quillet-Mary
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.,Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France
| | - L Ysebaert
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.,Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France.,Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, France
| | - M Poupot
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.,Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France
| |
Collapse
|
20
|
Caminade AM, Fruchon S, Turrin CO, Poupot M, Ouali A, Maraval A, Garzoni M, Maly M, Furer V, Kovalenko V, Majoral JP, Pavan GM, Poupot R. The key role of the scaffold on the efficiency of dendrimer nanodrugs. Nat Commun 2015; 6:7722. [PMID: 26169490 PMCID: PMC4510975 DOI: 10.1038/ncomms8722] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 06/04/2015] [Indexed: 12/29/2022] Open
Abstract
Dendrimers are well-defined macromolecules whose highly branched structure is reminiscent of many natural structures, such as trees, dendritic cells, neurons or the networks of kidneys and lungs. Nature has privileged such branched structures for increasing the efficiency of exchanges with the external medium; thus, the whole structure is of pivotal importance for these natural networks. On the contrary, it is generally believed that the properties of dendrimers are essentially related to their terminal groups, and that the internal structure plays the minor role of an ‘innocent' scaffold. Here we show that such an assertion is misleading, using convergent information from biological data (human monocytes activation) and all-atom molecular dynamics simulations on seven families of dendrimers (13 compounds) that we have synthesized, possessing identical terminal groups, but different internal structures. This work demonstrates that the scaffold of nanodrugs strongly influences their properties, somewhat reminiscent of the backbone of proteins. The biological properties of dendrimers are thought to be largely dependent on the chemical nature of their surface. Here, the authors show that the internal scaffold of dendritic nanodrugs strongly influences their bioactivity, based on convergent information from biology and computation results.
Collapse
Affiliation(s)
- Anne-Marie Caminade
- 1] Laboratoire de Chimie de Coordination du CNRS, UPR 8241, 205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France [2] Université de Toulouse, UPS, INP, LCC, F-31077 Toulouse, France
| | - Séverine Fruchon
- 1] Centre de Physiopathologie de Toulouse Purpan, F-31300 Toulouse, France [2] INSERM, U1043; CNRS, U5282; Université de Toulouse, UPS, Toulouse, France
| | - Cédric-Olivier Turrin
- 1] Laboratoire de Chimie de Coordination du CNRS, UPR 8241, 205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France [2] Université de Toulouse, UPS, INP, LCC, F-31077 Toulouse, France
| | - Mary Poupot
- 1] Centre de Recherche en Cancérologie de Toulouse, F-31300 Toulouse, France [2] INSERM, U1037; CNRS, U5294; Université de Toulouse, UPS, Toulouse, France
| | - Armelle Ouali
- 1] Laboratoire de Chimie de Coordination du CNRS, UPR 8241, 205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France [2] Université de Toulouse, UPS, INP, LCC, F-31077 Toulouse, France
| | - Alexandrine Maraval
- 1] Laboratoire de Chimie de Coordination du CNRS, UPR 8241, 205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France [2] Université de Toulouse, UPS, INP, LCC, F-31077 Toulouse, France
| | - Matteo Garzoni
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Galleria 2, 6928 Manno, Switzerland
| | - Marek Maly
- Faculty of Science, J.E. Purkinje University, Ceske mladeze 8, 400 96 Ústí nad Labem, Czech Republic
| | - Victor Furer
- Kazan State Architect and Civil Engineering University, Zelenaya 1, Kazan 420043, Russia
| | - Valeri Kovalenko
- A.E. Arbuzov Institute of Organic and Physical Chemistry of Kazan Scientific Center of Russian Academy of Science, Arbuzov Str., 8, Kazan 420088, Russia
| | - Jean-Pierre Majoral
- 1] Laboratoire de Chimie de Coordination du CNRS, UPR 8241, 205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France [2] Université de Toulouse, UPS, INP, LCC, F-31077 Toulouse, France
| | - Giovanni M Pavan
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Galleria 2, 6928 Manno, Switzerland
| | - Rémy Poupot
- 1] Centre de Physiopathologie de Toulouse Purpan, F-31300 Toulouse, France [2] INSERM, U1043; CNRS, U5282; Université de Toulouse, UPS, Toulouse, France
| |
Collapse
|
21
|
Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Gastroenterology 2015; 148:1452-65. [PMID: 25683115 DOI: 10.1053/j.gastro.2015.02.009] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 02/04/2015] [Accepted: 02/06/2015] [Indexed: 12/17/2022]
Abstract
BACKGROUND & AIMS The KRAS gene is mutated in most pancreatic ductal adenocarcinomas (PDAC). Expression of this KRAS oncoprotein in mice is sufficient to initiate carcinogenesis but not progression to cancer. Activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is required for KRAS for induction and maintenance of PDAC in mice. The somatostatin receptor subtype 2 (sst2) inhibits PI3K, but sst2 expression is lost during the development of human PDAC. We investigated the effects of sst2 loss during KRAS-induced PDAC development in mice. METHODS We analyzed tumor growth in mice that expressed the oncogenic form of KRAS (KRAS(G12D)) in pancreatic precursor cells, as well as sst2+/- and sst2-/-, and in crossed KRAS(G12D);sst2+/- and KRAS(G12D);sst2-/- mice. Pancreatic tissues and acini were collected and assessed by histologic, immunoblot, immunohistochemical, and reverse-transcription polymerase chain reaction analyses. We also compared protein levels in paraffin-embedded PDAC samples from patients vs heathy pancreatic tissues from individuals without pancreatic cancer. RESULTS In sst2+/- mice, PI3K was activated and signaled via AKT (PKB; protein kinase B); when these mice were crossed with KRAS(G12D) mice, premalignant lesions, tumors, and lymph node metastases developed more rapidly than in KRAS(G12D) mice. In crossed KRAS(G12D);sst2+/- mice, activation of PI3K signaling via AKT resulted in activation of nuclear factor-κB (NF-κB), which increased KRAS activity and its downstream pathways, promoting initiation and progression of neoplastic lesions. We found this activation loop to be mediated by PI3K-induced production of the chemokine CXCL16. Administration of a CXCL16-neutralizing antibody to KRAS(G12D) mice reduced activation of PI3K signaling to AKT and NF-κB, blocking carcinogenesis. Levels of CXCL16 and its receptor CXCR6 were significantly higher in PDAC tissues and surrounding acini than in healthy pancreatic tissues from mice or human beings. In addition, expression of sst2 was progressively lost, involving increased PI3K activity, in mouse lesions that expressed KRAS(G12D) and progressed to PDAC. CONCLUSIONS Based on analyses of mice, loss of sst2 from pancreatic tissues activates PI3K signaling via AKT, leading to activation of NF-κB, amplification of oncogenic KRAS signaling, increased expression of CXCL16, and pancreatic tumor formation. CXCL16 might be a therapeutic target for PDAC.
Collapse
Affiliation(s)
- Mounira Chalabi-Dchar
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Stéphanie Cassant-Sourdy
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Camille Duluc
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Marjorie Fanjul
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Hubert Lulka
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Rémi Samain
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Catherine Roche
- UMR7286 CNRS-Aix-Marseille University, Neurobiology and Neurophysiology Research Center of Marseille, and Laboratory of Molecular Biology, AP-HM Conception, Marseille, France
| | | | | | - Mary Poupot
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Marlène Dufresne
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Takeshi Shimaoka
- Department of Molecular Preventive Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan
| | - Shin Yonehara
- Laboratory of Molecular and Cellular Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| | - Muriel Mathonnet
- EA 3842 Laboratory, Medicine and Pharmacy Faculties, Limoges University, Limoges, France
| | - Stéphane Pyronnet
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Corinne Bousquet
- INSERM UMR-1037, Toulouse University, Cancer Research Center of Toulouse, Equipe Labellisée Ligue Contre le Cancer and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France.
| |
Collapse
|
22
|
Abstract
CD14 + cells are able to differentiate into large and adherent cells if in contact with chronic lymphocytic leukemia (CLL) cells or healthy B lymphocytes. In CLL these cells, called CLL-nurse like cells (NLCs), express a very high amount of CD163 and CD68 and are able to rescue CLL cells through CCL4 production. Adherent cells derived from healthy donors, called HD-NLCs, express very little CD163 and CD68, do not produce CCL4 and are unable to rescue CCL cells. This study reveals that CLL-NLCs are the specific nurse cells in CLL, protecting CLL cells from death.
Collapse
Affiliation(s)
- Frédéric Boissard
- INSERM UMR1037 - Cancer Research Center of Toulouse , Toulouse , France
| | | | | | | | | |
Collapse
|
23
|
Poupot M, Boissard F, Betous D, Bardouillet L, Fruchon S, L'Faqihi-Olive F, Pont F, Mekaouche M, Ingoure S, Sicard H, Dubreuilh G, Fournié JJ. The PPARα pathway in Vγ9Vδ2 T cell anergy. Cell Mol Biol Lett 2014; 19:649-58. [PMID: 25424910 PMCID: PMC6275808 DOI: 10.2478/s11658-014-0218-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 10/30/2014] [Indexed: 11/22/2022] Open
Abstract
Phosphoantigens (PAgs) activate Vγ9Vδ2 T lymphocytes, inducing their potent and rapid response in vitro and in vivo. However, humans and nonhuman primates that receive repeated injections of PAgs progressively lose their Vγ9Vδ2 T cell response to them. To elucidate the molecular mechanisms of this in vivo desensitization, we analyzed the transcriptome of circulating Vγ9Vδ2 T cells from macaques injected with PAg. We showed that three PAg injections induced the activation of the PPARα pathway in Vγ9Vδ2 T cells. Thus, we analyzed the in vitro response of Vγ9Vδ2 T cells stimulated with a PPARα agonist. We demonstrated that in vitro PPARα pathway activation led to the inhibition of the BrHPP-induced activation and proliferation of human Vγ9Vδ2 T cells. Since the PPARα pathway is involved in the antigen-selective desensitization of human Vγ9Vδ2 T cells, the use of PPARα inhibitors could enhance cancer immunotherapy based on Vγ9Vδ2 T cells.
Collapse
Affiliation(s)
- Mary Poupot
- INSERM UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Decaup E, Duault C, Bezombes C, Poupot M, Savina A, Olive D, Fournié JJ. Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Immunol Lett 2014; 161:133-7. [DOI: 10.1016/j.imlet.2014.05.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 05/14/2014] [Accepted: 05/19/2014] [Indexed: 11/26/2022]
|
25
|
Camus M, Pourcelot P, Falala S, Ravary-Plumioen B, Poupot M, Denoix JM, Chateau H, Crevier-Denoix N. Comparison of the moment at the distal interphalangeal joint on asphalt and on sand in horses at trot. Comput Methods Biomech Biomed Engin 2013; 16 Suppl 1:142-4. [DOI: 10.1080/10255842.2013.815980] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Poupot M, Fruchon S, Boissard F, Aruebo ME, Cendron D, El Faqihi-Olive F, Pont F, Bardouillet L, Mekaouche M, Ingoure S, Sicard H, Dubreuilh G, Fournie JJ. Molecular mechanism of the Vγ9Vδ2 T lymphocytes anergy. (P4385). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.205.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Upon activation with phosphoantigens (PAgs), human and non-human primates circulating TCRVγ9Vδ2 T lymphocytes release pro-inflammatory cytokines, mediate tumor cell cytotoxicity and proliferate through an IL2-dependent clonal expansion. Together, these features make it versatile and attractive candidates for new cancer immunotherapies (Kabelitz, D et al., 2007, Canc.Res., 67(1):5-8). Despite a potent and rapid response of the TCRVγ9Vδ2 T lymphocytes in vitro and in vivo, repeated stimulations with PAgs desensitize selectively this T cell lineage in humans and non-human primates (Cendron, D. et al., 2007, Eur.J.Immunol., 37(2):549-65; Sicard, H. et al., 2005, J.Immunol., 175(8):5471-80). Thus, we investigated the gene expression pattern associated with this PAg-selective anergy of these lymphocytes. TCRVγ9Vδ2 T cells were isolated from blood samples from PAgs-injected macaques (3 repeated injections) for transcriptome studies. After the third stimulation, in addition to some genes corresponding to the inhibition of cell cycle, a significant gene signature emerged from the desensitized γδ T cells transcriptome involving the PPARα and CARM1 pathways, based on up-regulation of both EP300, HSD17B4, PRKAR2B and RB1 genes while RARA and PRKCA (PKCα) were down-regulated. Moreover, inhibition of proliferation and cytokine production by PPARα agonists-treated human TCRVγ9Vδ2 T lymphocytes confirmed the implication of PPARα pathway in the γδ T cells desensitization by PAgs.
Collapse
Affiliation(s)
- Mary Poupot
- 1CRCT UMR1037, Inserm-CNRS-Univ. Med, Toulouse, France
| | | | | | | | | | | | - Frederic Pont
- 1CRCT UMR1037, Inserm-CNRS-Univ. Med, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 2012; 10:35-41. [PMID: 23241899 DOI: 10.1038/cmi.2012.39] [Citation(s) in RCA: 130] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
During the last several years, research has produced a significant amount of knowledge concerning the characteristics of human γδ T lymphocytes. Findings regarding the immune functions of these cells, particularly their natural killer cell-like lytic activity against tumor cells, have raised expectations for the therapeutic applications of these cells for cancer. Pharmaceutical companies have produced selective agonists for these lymphocytes, and several teams have launched clinical trials of γδ T cell-based cancer therapies. The findings from these studies include hematological malignancies (follicular lymphoma, multiple myeloma, acute and chronic myeloid leukemia), as well as solid tumors (renal cell, breast and prostate carcinomas), consisting of samples from more than 250 patients from Europe, Japan and the United States. The results of these pioneering studies are now available, and this short review summarizes the lessons learned and the role of γδ T cell-based strategies in the current landscape of cancer immunotherapies.
Collapse
|
28
|
Hayder M, Poupot M, Baron M, Turrin CO, Caminade AM, Majoral JP, Eisenberg RA, Fournié JJ, Cantagrel A, Poupot R, Davignon JL. Frequency and route of administration in the treatment of experimental arthritis by phosphorus-based dendrimer. Ann Rheum Dis 2012. [DOI: 10.1136/annrheumdis-2011-201230.18] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Pont F, Familiades J, Déjean S, Fruchon S, Cendron D, Poupot M, Poupot R, L'faqihi-Olive F, Prade N, Ycart B, Fournié JJ. The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures. Eur J Immunol 2011; 42:228-40. [PMID: 21968650 DOI: 10.1002/eji.201141870] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2011] [Revised: 08/12/2011] [Accepted: 09/26/2011] [Indexed: 12/28/2022]
Abstract
Global transcriptional technologies have revolutionised the study of lymphoid cell populations, but human γδ T lymphocytes specific for phosphoantigens remain far less deeply characterised by these methods despite the great therapeutic potential of these cells. Here we analyse the transcriptome of circulating TCRVγ(+) γδ T cells isolated from healthy individuals, and their relation with those from other lymphoid cell subsets. We report that the gene signature of phosphoantigen-specific TCRVγ(+) γδ T cells is a hybrid of those from αβ T and NK cells, with more 'NK-cell' genes than αβ T cells have and more 'T-cell' genes than NK cells. The expression profile of TCRVγ(+) γδ T cells stimulated with phosphoantigen recapitulates their immediate physiological functions: Th1 cytokine, chemokine and cytotoxic activities reflect their high mitotic activity at later time points and do not indicate antigen-presenting functions. Finally, such hallmarks make the transcriptome of γδ T cells, whether resting or clonally expanding, clearly distinctive from that of NK/T or peripheral T-cell lymphomas of the γδ subtype.
Collapse
Affiliation(s)
- Fréderic Pont
- INSERM UMR1037, Cancer Research Center of Toulouse, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Dendrimers are polybranched and polyfunctionalized tree-like polymers. Unlike linear polymers, they have perfectly defined structure and molecular weight, due to their iterative step-by-step synthesis. Their multivalent structure and supramolecular properties have made them attractive nanotools for applications, particularly in biology and medicine. Among the different biological and medical properties of dendrimers that have been developed over the past decades, the anti-inflammatory properties of several groups of dendrimers are the most recently discovered. Thereof, dendrimers emerge as promising, although heretical, drug candidates for the treatment of still-uncured chronic inflammatory disorders. This mini-review is based on the five main scientific articles giving an overview of what can be the spectrum of anti-inflammatory characteristics displayed by dendrimers.
Collapse
Affiliation(s)
- Myriam Hayder
- Inserm, U1043, CNRS, U5282 and Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France
| | | | | | | | | |
Collapse
|
31
|
Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, Majoral JP, Eisenberg RA, Fournie JJ, Cantagrel A, Poupot R, Davignon JL. A Phosphorus-Based Dendrimer Targets Inflammation and Osteoclastogenesis in Experimental Arthritis. Sci Transl Med 2011; 3:81ra35. [DOI: 10.1126/scitranslmed.3002212] [Citation(s) in RCA: 182] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
32
|
Lis R, Capdet J, Mirshahi P, Lacroix-Triki M, Dagonnet F, Klein C, Mirshahi M, Fournié JJ, Rafii A, Poupot M. Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells. Int J Oncol 2011; 37:1453-61. [PMID: 21042713 DOI: 10.3892/ijo_00000797] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
In breast cancers, the appearance of metastasis is synonymous with poor prognosis. The metastatic process is usually associated with epithelial-mesenchymal transition (EMT) which is often induced by several soluble factors produced either by the tumour cells themselves or by cells constituting the tumour microenvironment. The aim of the present study was to determine whether the mesenchymal properties given by some molecules such as N-cadherin, for instance, could be acquired by cancer cells via the trogocytosis process with cells of the tumour microenvironment. Hospicells are stromal cells which were first isolated from cancer cell aggregates of patients with ovarian cancer. We recently showed that these cells are immunosuppressive for T lymphocyte functions and confer chemoresistance to cancer cells by the transfer of the MDR protein via trogocytosis. In this study, we showed that a mammary cancer cell line (MDA-MB-231) acquires patches of membrane via oncologic trogocytosis with Hospicells. This unidirectional and active process depends on actin polymerization and can be increased via inhibition of the Src family and decreased via inhibition of PI3K. Trogocytosis between Hospicells and MDA-MB-231 does not lead to the direct acquisition of N-cadherin but rather it leads to the production of soluble factor(s) which induce de novo expression of N-cadherin by the cancer cells. The novelty here is that this factor is produced only if cancer cells interact and undergo trogocytosis with Hospicells. This new expression could confer a more invasive phenotype to the cancer cells and thus can explain the correlation of the presence of Hospicells with the number of invaded lymph nodes in patients with mammary adenocarcinoma.
Collapse
Affiliation(s)
- Raphaël Lis
- INSERM U563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse F-31300, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Dauguet N, Récher C, Demur C, Fournié J, Poupot M, Poupot R. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. Am J Hematol 2011; 86:209-13. [PMID: 21264910 DOI: 10.1002/ajh.21906] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Revised: 10/13/2010] [Accepted: 10/13/2010] [Indexed: 11/10/2022]
Abstract
Despite substantial progress in the treatment of AML, a proportion of patients do not achieve first complete remission (1(st) CR) with the induction chemotherapy, and, among patients achieving it, a majority is expected to relapse within three years. As allogeneic hematopoietic stem cell transplantation has been established as the most effective form of antileukemic therapy in patients with AML in remission, many studies have focused on the reconstitution and the functionality of the innate immune system in this context, especially regarding cytotoxic effectors such as natural killer (NK) cells. On the contrary, very few data are available concerning the innate immune system of patients in 1st CR. Herein we investigated the phenotype of autologous NK cells of AML patients in 1st CR. We showed that immature NK cells were pre-eminent in the blood of these patients and that this immature phenotype was persistent during the first months after 1st CR.
Collapse
Affiliation(s)
- Nicolas Dauguet
- INSERM, U.563, Centre de Physiopathologie de Toulouse‐Purpan, Toulouse, F‐31300 France, Université Paul‐Sabatier, Toulouse, F‐31400 France
| | - Christian Récher
- Department of Clinical Hematology, Toulouse University Hospital, Toulouse, F‐31300 France
| | - Cécile Demur
- Department of Clinical Hematology, Toulouse University Hospital, Toulouse, F‐31300 France
| | - Jean‐Jacques Fournié
- INSERM, U.563, Centre de Physiopathologie de Toulouse‐Purpan, Toulouse, F‐31300 France, Université Paul‐Sabatier, Toulouse, F‐31400 France
| | - Mary Poupot
- INSERM, U.563, Centre de Physiopathologie de Toulouse‐Purpan, Toulouse, F‐31300 France, Université Paul‐Sabatier, Toulouse, F‐31400 France
| | - Rémy Poupot
- INSERM, U.563, Centre de Physiopathologie de Toulouse‐Purpan, Toulouse, F‐31300 France, Université Paul‐Sabatier, Toulouse, F‐31400 France
| |
Collapse
|
34
|
Turrin C, Caminade A, Majoral J, Poupot M, Fournié J, Poupot R. R116: Immuno-modulations induites par des dendrimères phosphorés. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31035-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ. Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. Curr Drug Targets 2010; 11:790-800. [PMID: 20370648 DOI: 10.2174/138945010791320845] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2009] [Accepted: 01/18/2010] [Indexed: 11/22/2022]
Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Collapse
|
36
|
Martinet L, Poupot R, Mirshahi P, Rafii A, Fournié JJ, Mirshahi M, Poupot M. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 2010; 126:2143-52. [PMID: 19739080 DOI: 10.1002/ijc.24881] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
With metastatic disease at diagnosis for 70% of patients, ovarian cancer represents the most lethal gynecological malignancy. Ovarian carcinomas are aggressive malignancies that can evade immune surveillance and frequently develop into metastases. The tumor microenvironment is decisive for preventing immune attack but, in the case of ovarian carcinoma, the mechanisms are unclear. We recently isolated a novel type of stromal cell from the ascitis of patients with ovarian carcinoma that interacts with epithelial ovarian cancers conferring them chemoresistance. These cells, called Hospicells, have the cell surface markers CD9, CD10, CD29, CD146 and CD166. Here, we investigated whether Hospicells also have immunomodulatory functions that might interfere with immunity to cancer. We report that Hospicells inhibit the proliferation of human CD4(+), CD8(+) and Vgamma9Vdelta2 T cells in vitro and the production of cytokines by these immune cells. The immunosuppression of CD4(+) T cells is independent of direct contact with the Hospicells and is mainly due to nitric oxide produced by the inducible nitric oxide synthase and to products of the tryptophan degradation by indoleamine 2,3-dioxygenase. We proposed that Hospicells in the microenvironment of the tumor mediate immunosuppression of T cells and thus allow ovarian cancers to evade immune surveillance. Targeting of Hospicells could be an alternative to strong chemotherapy through the recovery of immune responses against tumor cells.
Collapse
Affiliation(s)
- Ludovic Martinet
- INSERM, U563, Centre de Physiopathologie de Toulouse-Purpan and Université Paul-Sabatier, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Dauguet N, Fournié JJ, Poupot R, Poupot M. Lenalidomide down regulates the production of interferon-γ and the expression of inhibitory cytotoxic receptors of human Natural Killer cells. Cell Immunol 2010; 264:163-70. [DOI: 10.1016/j.cellimm.2010.06.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2010] [Revised: 06/07/2010] [Accepted: 06/14/2010] [Indexed: 12/22/2022]
|
38
|
Marchand P, Griffe L, Poupot M, Turrin CO, Bacquet G, Fournié JJ, Majoral JP, Poupot R, Caminade AM. Dendrimers ended by non-symmetrical azadiphosphonate groups: Synthesis and immunological properties. Bioorg Med Chem Lett 2009; 19:3963-6. [DOI: 10.1016/j.bmcl.2009.03.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2009] [Revised: 02/27/2009] [Accepted: 03/03/2009] [Indexed: 10/21/2022]
|
39
|
Rolland O, Turrin CO, Bacquet G, Poupot R, Poupot M, Caminade AM, Majoral JP. Efficient synthesis of phosphorus-containing dendrimers capped with isosteric functions of amino-bismethylene phosphonic acids. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2009.02.127] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujade-Lauraine E, Favre G, Soria J, Mirshahi M. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008; 3:e3894. [PMID: 19079610 PMCID: PMC2597737 DOI: 10.1371/journal.pone.0003894] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2008] [Accepted: 11/04/2008] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The microenvironment plays a major role in the onset and progression of metastasis. Epithelial ovarian cancer (EOC) tends to metastasize to the peritoneal cavity where interactions within the microenvironment might lead to chemoresistance. Mesothelial cells are important actors of the peritoneal homeostasis; we determined their role in the acquisition of chemoresistance of ovarian tumours. METHODOLOGY/PRINCIPAL FINDINGS We isolated an original type of stromal cells, referred to as "Hospicells" from ascitis of patients with ovarian carcinosis using limiting dilution. We studied their ability to confer chemoresistance through heterocellular interactions. These stromal cells displayed a new phenotype with positive immunostaining for CD9, CD10, CD29, CD146, CD166 and Multi drug resistance protein. They preferentially interacted with epithelial ovarian cancer cells. This interaction induced chemoresistance to platin and taxans with the implication of multi-drug resistance proteins. This contact enabled EOC cells to capture patches of the Hospicells membrane through oncologic trogocytosis, therefore acquiring their functional P-gp proteins and thus developing chemoresistance. Presence of Hospicells on ovarian cancer tissue micro-array from patients with neo-adjuvant chemotherapy was also significantly associated to chemoresistance. CONCLUSIONS/SIGNIFICANCE This is the first report of trogocytosis occurring between a cancer cell and an original type of stromal cell. This interaction induced autonomous acquisition of chemoresistance. The presence of stromal cells within patient's tumour might be predictive of chemoresistance. The specific interaction between cancer cells and stromal cells might be targeted during chemotherapy.
Collapse
Affiliation(s)
- Arash Rafii
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
- LFR 44, IFR 31, Institut Claudius Regaud, Toulouse, France
- Department of Genetic Medicine and Obstetrics and Gynecology, WCMC-Qatar, Qatar Foundation, Doha, Qatar
| | - Pejman Mirshahi
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Mary Poupot
- INSERM U563, Centre de Physiopathologie de Toulouse Purpan, CHU Purpan, BP3028, Toulouse, France
| | - Anne-Marie Faussat
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Anne Simon
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Elodie Ducros
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Eliane Mery
- LFR 44, IFR 31, Institut Claudius Regaud, Toulouse, France
| | - Bettina Couderc
- INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud & Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Raphael Lis
- INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud & Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Jerome Capdet
- INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud & Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Julie Bergalet
- INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud & Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Denis Querleu
- LFR 44, IFR 31, Institut Claudius Regaud, Toulouse, France
| | - Francoise Dagonnet
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Jean-Jacques Fournié
- INSERM U563, Centre de Physiopathologie de Toulouse Purpan, CHU Purpan, BP3028, Toulouse, France
| | - Jean-Pierre Marie
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Eric Pujade-Lauraine
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Gilles Favre
- INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud & Faculté des Sciences Pharmaceutiques, Toulouse, France
| | - Jeanine Soria
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
| | - Massoud Mirshahi
- UMRS 872 INSERM, Université Pierre et Marie Curie-Paris 6 and Université Paris Descartes, Equipe 18, Centre de Recherche des Cordeliers, Paris, France
- * E-mail:
| |
Collapse
|
41
|
Fruchon S, Poupot M, Martinet L, Turrin CO, Majoral JP, Fournié JJ, Caminade AM, Poupot R. Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. J Leukoc Biol 2008; 85:553-62. [DOI: 10.1189/jlb.0608371] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Abstract
Cross-regulations between innate immune cells have been given more and more emphasis. Here, we address the question of bidirectional interactions between activated monocytes and autologous NK cells. Classically activated monocytes (class-monocytes), obtained by priming with IFN-gamma, drive an inflammatory immune response. On the contrary, alternatively activated monocytes (alt-monocytes), obtained by stimulation with IL-4 or IL-13, engage an anti-inflammatory immune response. We show that alt-monocytes inhibit proliferation and production of IFN-gamma by autologous, IL-2-activated NK cells, whereas class-monocytes do not inhibit these NK cell functions. Reciprocally, IL-2-activated NK cells interact and undertake intensive synaptic transfer with alt-monocytes, whereas interactions with class-monocytes are weaker. This strong trogocytosis correlates with an efficient killing of alt-monocytes, mediated by natural cytotoxicity receptors and a lowered killing of class-monocytes. These results suggest that interactions between NK cells and autologous-activated monocytes modulate inflammatory responses. This might be extended further in the elimination of tumor-associated macrophages, which actively promote solid tumor progression and metastasis.
Collapse
Affiliation(s)
- Mary Poupot
- INSERM, U.563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France
| | | | | |
Collapse
|
43
|
Rolland O, Griffe L, Poupot M, Maraval A, Ouali A, Coppel Y, Fournié JJ, Bacquet G, Turrin CO, Caminade AM, Majoral JP, Poupot R. Tailored Control and Optimisation of the Number of Phosphonic Acid Termini on Phosphorus-Containing Dendrimers for the Ex-Vivo Activation of Human Monocytes. Chemistry 2008; 14:4836-50. [DOI: 10.1002/chem.200701063] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
44
|
Abstract
Cell-to-cell transfers of membrane molecules between lymphoid cells (sometimes referred to as trogocytosis) is frequent and has multiple physiological consequences. Although difficult to visualize through the tracking of defined cell surface proteins, this process can be readily monitored by inserting PKH or CellVue Maroon fluorochromes into the plasma membranes of donor cells. We discuss here parameters that determine its detection by a flow-cytometry-based in vitro assay and present examples of application, including time-lapse video-microscopy analysis of transfers at the immunological synapse. By combining detection of cell-to-cell transfer and of cell surface CD107, it is possible to discriminate lymphoid cells binding target cells with and without perforin release. This could prove useful for identifying cells that destruct known target cells in autoimmune pathologies.
Collapse
Affiliation(s)
- Julie Gertner-Dardenne
- Innate Immunity, Malignant Hemopathies and Cancer Immunity, Department of Oncology, Institut National de la Santé Et de la Recherche Médicale Unit 563, Toulouse, Cedex, France
| | | | | | | |
Collapse
|
45
|
Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Métivier P, Bacquet G, Fournié JJ, Caminade AM, Poupot R, Majoral JP. Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew Chem Int Ed Engl 2007; 46:2523-6. [PMID: 17300122 DOI: 10.1002/anie.200604651] [Citation(s) in RCA: 120] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Laurent Griffe
- Laboratoire de Chimie de Coordination, CNRS, 205 route de Narbonne, 31077 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gertner J, Wiedemann A, Poupot M, Fournié JJ. Human γδ T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 2007; 110:42-53. [PMID: 17451812 DOI: 10.1016/j.imlet.2007.03.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2007] [Revised: 02/20/2007] [Accepted: 03/05/2007] [Indexed: 11/19/2022]
Abstract
When human gammadelta lymphocytes bind to tumor cells for killing, they also strip their membrane for unknown reasons. Here we investigated this topic using the model of human gammadelta lymphocytes co-incubated with anaplastic large cell lymphomas, a group of tumors with cytolytic T or null lineage. By using flow cytometry and live cell imaging, we show that as soon as both cells were in contact, the TCR-mediated activation of gammadelta lymphocytes simultaneously triggered their secretion of lytic granules and stripping of lymphoma cell membranes, and both activities continued even after their cell death. However reciprocally in such conjugates, resistant lymphoma failed to strip gammadelta cells and to kill them by untargeted secretion of their own lytic granules. This indicated that secretion of lytic granules and target membrane stripping are associated in lytic cell conjugates, and that gammadelta T lymphocytes strip and kill their targets simultaneously.
Collapse
Affiliation(s)
- Julie Gertner
- Department of Oncology, Institut National de la Santé Et de la Recherche Médicale Unité 563, BP 3128, Hopital Purpan, 31024 Toulouse Cedex 03, France
| | | | | | | |
Collapse
|
47
|
Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Métivier P, Bacquet G, Fournié JJ, Caminade AM, Poupot R, Majoral JP. Multiplication of Human Natural Killer Cells by Nanosized Phosphonate-Capped Dendrimers. Angew Chem Int Ed Engl 2007. [DOI: 10.1002/ange.200604651] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
48
|
Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Métivier P, Bacquet G, Fournié JJ, Caminade AM, Poupot R, Majoral JP. Innentitelbild: Multiplication of Human Natural Killer Cells by Nanosized Phosphonate-Capped Dendrimers (Angew. Chem. 14/2007). Angew Chem Int Ed Engl 2007. [DOI: 10.1002/ange.200790051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
49
|
Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Métivier P, Bacquet G, Fournié JJ, Caminade AM, Poupot R, Majoral JP. Inside Cover: Multiplication of Human Natural Killer Cells by Nanosized Phosphonate-Capped Dendrimers (Angew. Chem. Int. Ed. 14/2007). Angew Chem Int Ed Engl 2007. [DOI: 10.1002/anie.200790051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
50
|
Poupot M, Griffe L, Marchand P, Maraval A, Rolland O, Martinet L, L'Faqihi-Olive FE, Turrin CO, Caminade AM, Fournié JJ, Majoral JP, Poupot R. Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB J 2006; 20:2339-51. [PMID: 17077311 DOI: 10.1096/fj.06-5742com] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
As first defensive line, monocytes are a pivotal cell population of innate immunity. Monocyte activation can be relevant to a range of immune conditions and responses. Here we present new insights into the activation of monocytes by a series of phosphonic acid-terminated, phosphorus-containing dendrimers. Various dendritic or subdendritic structures were synthesized and tested, revealing the basic structural requirements for monocyte activation. We showed that multivalent character and phosphonic acid capping of dendrimers are crucial for monocyte targeting and activation. Confocal videomicroscopy showed that a fluorescein-tagged dendrimer binds to isolated monocytes and gets internalized within a few seconds. We also found that dendrimers follow the phagolysosomial route during internalization by monocytes. Finally, we performed fluorescence resonance energy transfer (FRET) experiments between a specifically designed fluorescent dendrimer and phycoerythrin-coupled antibodies. We showed that the typical innate Toll-like receptor (TLR)-2 is clearly involved, but not alone, in the sensing of dendrimers by monocytes. In conclusion, phosphorus-containing dendrimers appear as precisely tunable nanobiotools able to target and activate human innate immunity and thus prove to be good candidates to develop new drugs for immunotherapies.
Collapse
Affiliation(s)
- Mary Poupot
- INSERM 563, Centre de Physiopathologie de Toulouse-Purpan, Hôpital Purpan, BP3028, 31024 Toulouse cedex 03, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|